{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Carmell Corp.
Carmell Corp. Stock Plummets to New 52-Week Low of $1.12
Carmell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting a significant decline over the past year. With a market capitalization of around USD 4 million, the company is currently loss-making and faces valuation concerns despite a high return on equity.
Carmell Corp. Hits New 52-Week Low at $1.21 Amidst Declining Performance
Carmell Corp., a microcap in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company reports negative earnings, a negative book value, and consistent losses, raising concerns about its financial stability and future prospects.
Is Carmell Corp. overvalued or undervalued?
As of March 31, 2025, Carmell Corp. is overvalued and classified as "does not qualify" due to a negative P/E ratio and poor financial metrics, including a Price to Book Value of -0.72, while its year-to-date return of -67.87% starkly contrasts with the S&P 500's gain of 2.44%.
Is Carmell Corp. technically bullish or bearish?
As of June 17, 2025, Carmell Corp. has shifted to a bearish trend, supported by bearish daily moving averages and Bollinger Bands, despite some mildly bullish MACD signals on longer time frames.
What does Carmell Corp. do?
Carmell Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $1 million and a net loss of $2 million. It has a market cap of $2.28 million and key metrics indicating a high return on equity but no dividends or earnings due to losses.
How big is Carmell Corp.?
As of Jun 18, Carmell Corp. has a market capitalization of 2.28 million, with net sales of 0.56 million and a net profit of -8.60 million over the last four quarters. Shareholder's funds are at -4.71 million, and total assets are 1.47 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
